A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM)

NCT06767735 | Active Not Recruiting Phase 3

• 1 other identifier: GZR4-T2D-301
• Study Type: interventional
• Target: 580
• Locations: 1 country
• Sites: 1

Brief Summary

This study will be conducted to compare the efficacy, safety and patient-reported outcome of once-weekly GZR4 and once-daily Insulin Glargine U100 with Non-Insulin Antidiabetic Agents in Insulin-naive Subjects with Type 2 Diabetes Mellitusin.

Conditions

Diabetes

Keywords

GZR4; insulin

Outcome Measures

Primary Outcomes (1)

• Change in HbA1c

  From baseline (week 0) to week 26

Secondary Outcomes (4)

• Change in HbA1c

  From baseline (week 0) to week 52

• hypoglycaemia events

  From baseline (week 0) to week 26/52

• adverse events

  From baseline (week 0) to week 26/52

• Change in weight

  From baseline (week 0) to week 26

Study Arms (2)

GZR4 group

EXPERIMENTAL

Drug: GZR4

Insulin Glargine U100 group

ACTIVE COMPARATOR

Drug: Insulin Glargine U100

Interventions

GZR4 DRUG

GZR4 s.c., once-weekly，treat-to-target dose

GZR4 group

Insulin Glargine U100 DRUG

Insulin Glargine U100 s.c.,once-daily，treat-to-target dose

Insulin Glargine U100 group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Sign the Informed Consent Form (ICF) before the study, fully understand the contents, process and possible adverse reactions of the study, and be able to follow the contraindications and restrictions specified in this protocol.
• Males and females age ≥ 18 years at the time of informed consent.
• The pregnancy test for β-human chorionic gonadotropin (hCG) must be negative for women of childbearing potential during the screening period and prior to randomization.
• From signing the Informed Consent Form until 3 weeks after the end of treatment, female subjects of childbearing potential and male subjects and their partners must agree to use reliable contraceptive measures and not donate eggs (ova, oocytes) or sperm for assisted reproductive purposes.
• According to the diagnostic criteria and classification of diabetes mellitus issued by the World Health Organization (WHO) in 1999, and the supplementary diagnostic criteria recommended by WHO for diagnosis with Hemoglobin A1c (HbA1c) (2011), the time to diagnose T2DM is ≥ 180 days at screening.
• Naive to insulin treatment.

You may not qualify if:

• A history of allergy to drugs with two or more mechanisms of action in the past, or known allergies, hypersensitivity, or intolerance to the investigational medicinal product or its excipients (glycerol, phenol, m-cresol, zinc acetate dihydrate, sodium chloride, citric acid monohydrate, or zinc chloride).
• Subjects who are pregnant, lactating or planning to become pregnant during the study at screening.
• Participated in any drug clinical study (received non-placebo medication during the study) within a recent period of time (90 days or 5 half-lives of the previous investigational medicinal product, whichever is longer), or plans to participate in another clinical study before completing all scheduled assessments in this clinical study.
• Underwent invasive cardiovascular or cerebrovascular procedures within 180 days before screening; or experienced acute heart failure, myocardial infarction, stroke, or hospitalization due to angina unstable, transient ischaemic attack, or other acute cardiovascular events within 180 days before screening; or have a history of chronic cardiac failure classified as New York Heart Association Class III or IV at screening; or plan to undergo coronary, carotid, or peripheral arterial revascularisation procedures during the study; or have clinically significant abnormalities on the electrocardiogram (ECG) that require treatment at screening (such as second-degree type II or third-degree atrioventricular block, ventricular fibrillation, ventricular flutter, atrial fibrillation, atrial flutter, Wolff-Parkinson-White syndrome, etc.).
• History of malignant tumors before screening (excluding adequately treated or resected non-metastatic basal or squamous cell skin cancer, cervical carcinoma in situ, or prostate cancer in situ) or the presence of underlying malignancy at screening.
• The patient with SBP ≥ 160 mmHg or DBP ≥ 100 mmHg during screening.
• Subjects who are unable to comply with the requirements of this protocol as judged by the investigator, or have any other conditions that the investigator considers inappropriate to participate in this study.

Sponsors & Collaborators

• Gan & Lee Pharmaceuticals.: lead

Study Sites (1)

Gan & Lee Pharmaceuticals Shandong Co., Ltd.

Linyi, Shandong, 276000, China

Location

MeSH Terms

Conditions

Diabetes Mellitus; Insulin Resistance

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Hyperinsulinism

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 5, 2025
• First Posted: January 10, 2025
• Study Start: February 17, 2025
• Primary Completion (Estimated): August 1, 2026
• Study Completion (Estimated): August 17, 2026
• Last Updated: November 28, 2025

Record last verified: 2025-11

Locations

CN (1)